Heart failure & cardiomyopathies
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
An erratum to this article was published (Eur Heart J, 9 Jun 2026 ↗)
Primary result · CV deathResult — go to the resultHazard ratio 0.83 95% CI 0.71–0.97Authors' conclusion
In ambulatory well-treated participants with HFrEF, vericiguat was associated with clinically meaningful reductions in the key secondary outcome of cardiovascular death, as well as all-cause mortality.
Study context
- Population
- Ambulatory patients with HF and reduced ejection fraction (HFrEF) without recent worsening
- Participants
- 6,105 patients
- Comparison
- Vericiguat vs placebo
- Primary endpoint
- CV death (pre-specified secondary endpoint of VICTOR)
- Follow-up
- Median 19.7 months (IQR 14.6-25.4)
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
CV death · median 19.7 months
Hazard ratio
0.83
95% CI 0.71–0.97
P = 0.020
Events by treatment group
Vericiguat
5.7 deaths per 100 patient-years
292 events
Placebo
6.8 deaths per 100 patient-years
346 events
Vericiguatvs Placebo
HR 0.83 (95% CI 0.71–0.97); P = 0.020
As reported in the abstract
Secondary outcomes
| Outcome | Vericiguat | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause death | 7.3 deaths per 100 patient-years | 8.6 deaths per 100 patient-years | 0.84 (0.74–0.97) | P = 0.015 | |
| SCD | 1.6 events per 100 patient-years | 2.2 events per 100 patient-years | 0.75 (0.56–0.99) | P = 0.042 | |
| HF-related death | 1.7 events per 100 patient-years | 2.4 events per 100 patient-years | 0.71 (0.54–0.94) | P = 0.016 | |
| 0.512Hazard ratio (log scale) |
Mortality across subgroups (incl. baseline therapy, NT-proBNP)
- Lower mortality consistent across subgroups including baseline therapy and baseline NT-proBNP levels
Original publication
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J. Published 30 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →